Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth

Sonoma Pharmaceuticals

16/06/2026 21:28

Overview
Healthcare product maker's Q4 revenue grew 48% yr/yr, driven by increased U.S. sales
Company's Q4 net loss improved 25% yr/yr, reflecting better financial performance
Q4 EBITDA loss narrowed 66% yr/yr, aided by cost management and operational discipline

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
U.S. SALES GROWTH - Q4 revenue increase was primarily driven by higher U.S. sales, attributed to new distributors selling company products
INTERNATIONAL GAINS - Revenue also rose in Europe and Rest of World, partially offset by declines in Asia and Latin America due to timing of customer orders
COST PRESSURES - Operating expenses increased, mainly due to inflation and salary-related increases in Mexico

Company press release: ID:nACS1G5h7a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
 
$5.60 mln
 
Q4 Net Income
 
-$581,000
 
Q4 EBITDA
 
-$183,000
 
Q4 Gross Profit
 
$2.20 mln
 
Q4 Operating Expenses
 
$2.50 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 1,233.3% above its June 15 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)